in this issue
Regions :: Western Europe :: Germany
Merck KGaA Builds Plant in Switzerland
12:41 PM MDT | July 25, 2007 | Chemical Week Editorial Staff
Merck KGaA says it will build a plant near Geneva to manufacture the company’s Erbitux monoclonal antibody cancer treatment. The announcement was made shortly after Merck KGaA completed the acquisition of a majority stake in biotechnology firm Serono (Geneva) and created a new division, Merck Serono (CW, Jan. 17, p. 23). Merck KGaA had previously planned to build the Erbitux plant at its Darmstadt, Germany...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee